WAVEMAN · COMPANY

ACIU · Ac Immune Sa

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

ACIU

Name: AC Immune SA (ACIU) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

AC Immune SA

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001651625

C-SUITE BUYING · 1☆ WATCH

INSIDER NET · 180D

-$27.9K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$27.9K over 180 days

more than 61% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

16 funds added or opened last quarter

below 73% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

3.5% of shares outstanding short · 18.2 days to cover · settled 2026-07-31

below 54% of Pharma & Biotech

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +29.4%

+29.4%12M

INSIDER BUYINSIDER SELL

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows a net $27.9K sold by insiders over 180 days, 16 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, AC Immune SA insiders sold a net $27.9K of stock across 3 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Pfeifer Andrea

Chief Executive Officer

SELL

2026-05-15

10,000.0

$27.9K

Pfeifer Andrea

Chief Executive Officer

SELL

2026-04-15

10,000.0

$31.4K

Pfeifer Andrea

Chief Executive Officer

BUY

2026-04-15

10,000.0

$31.4K

3 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BVF INC/IL

19,822,436.0 sh

$47.2M

WELLS FARGO & COMPANY/MN

1,004,041.0 sh

$2.4M

RENAISSANCE TECHNOLOGIES LLC

840,127.0 sh

$2.0M

MILLENNIUM MANAGEMENT LLC

773,594.0 sh

$1.8M

BlackRock, Inc.

519,274.0 sh

$1.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco Nasdaq Biotechnology ETF

$16.4K POSITION · AS OF 2026-02-28

0.0%

Dimensional US Vector Equity ETF

$10.3K POSITION · AS OF 2026-04-30

0.0%

Dimensional U.S. Small Cap ETF

$244.6K POSITION · AS OF 2026-04-30

0.0%

Dimensional US Core Equity 1 ETF

$17.4K POSITION · AS OF 2026-04-30

0.0%

Dimensional US Sustainability Core 1 ETF

$8.6K POSITION · AS OF 2026-04-30

0.0%

Dimensional US Core Equity Market ETF

$25.1K POSITION · AS OF 2026-04-30

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 6 registered trials, 5 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

1 ACTIVE

Phase 2

1 ACTIVE

Early Phase 1

2 ACTIVE

Multi-phase

1 ACTIVE

What changed recently

A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune

2026-09-03 · Completion moved 2026-08 → 2026-12

Phase 1

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
NET INCOME	$-70.4M	$-50.9M	$-54.2M	$-70.8M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE